Jun 30, 2022

Tech.eu Tech.eu Insights creates insight and guides strategies with its comprehensive content and reports. Browse popular Insights content. French digital clinic Charles.co gets a shot of €7 million to make men’s health solutions more accessible The men's health clinic will expand its platform beyond sexual health services to include other chronic conditions post the funding Paris-based digital clinic entirely dedicated to men’s health issues, Charles.co has brought in €7 million in a seed-stage funding. The funding will allow the startup to expand its offerings and build out its team, which has already supported 50,000 men in combating chronic conditions such as erectile dysfunction or insomnia. The round was led by Kurma Partners and Speedinvest . Founded in 2019 by Simon Burellier and Olivier Algoud , Charles.co is a digital clinic that addresses chronic health issues in men, such as sexual health, hair loss, or insomnia. The startup offers all its services via an integrated digital platform developed in close collaboration with prominent medical experts on men’s health. The company wants to become the go-to brand for men’s health across Europe. Currently, more than six million men are already using the platform’s medical information each month. As more startups join the race to offer solutions for men’s health, the company is competing with the likes of Numan, which raised $13 million and Manual which raised $30 million last year. Charles.co co-founder Simon Burellier said: “Rapid treatment often means better care, but unfortunately many men feel uncomfortable going for consultations for chronic conditions. The goal of Charles.co is to reconnect men with their health and to offer them a safe, easily accessible space where they can get information, consult remotely and receive complete support for their medical issues.” Benjamin Belot , associate director at Kurma Partners added: “Given the shortage of specialists for men’s health, Charles.co is offering men a new way to access healthcare for some of their most sensitive problems, allowing them a confidential and effective treatment route.”